Foley’s Insurance attorneys share a deep industry knowledge and provide legal solutions reflecting and anticipating all aspects of an insurer’s operations. The CLE presentations for this daylong event covered a vast range of topics that touched upon every facet of the insurance industry, such as, cannabis insurance, privacy law developments, reinsurance structures, diversity & inclusion, and much more!
Topics Included:
- Market for Cannabis Insurance
- Michael Kasdin | Partner | Foley
- Robert H. Easton | Chief Compliance Officer, Risk and Insurance Services Segment | Marsh & McLennan Companies, Inc.
- John Kastl | Co-Founder | American Specialty Agriculture LLC
- Privacy Law Developments
- Jen Rathburn | Partner | Foley
- Lionel Weaver | Associate Counsel | Sentry Insurance
- Sabrina Guenther Frigo | Associate General Counsel, Privacy and Data Management | CUNA Mutual Group
- Brian Grill | House Counsel | Acuity Insurance
- What Should I Know About Insuretech?
- JillAllison Opell | Partner | Foley
- Brendan Gallagher | President | Arthur J. Gallagher & Co
- Matt Grossberg | Managing Partner | Ins Strategies
- Reinsurance in M&A – A Perspective in Time
- Kevin Fitzgerald | Partner | Foley
- Morgan Tilleman | Senior Counsel | Foley
- Bobby Bray, Vice President | Insurance-Linked Securities Origination & Structuring | Guy Carpenter Securities
- Diversity and Inclusion
- Sara Madavo | Senior Counsel | Foley
- Jeffrey Gearheart | Senior Vice President, Underwriting | Renaissance Reinsurance
- Ethics
- Will Lopez | Deputy General Counsel | Foley
People
Related Insights
23 October 2024
Health Care Law Today
Private Equity Investments in Oncology: Top Five Things to Know
Although private equity (PE) sponsors have been active investors in the health care services industry for the last decade, PE-backed health care providers today constitute only 4% of the United States health market by revenue.
23 October 2024
Health Care Law Today
GLP-1 Drugs: FDA Sued Over Removing Tirzepatide from the Drug Shortage List
Less than a week after the FDA determined that the shortage of the tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been “resolved” and removed from the FDA’s shortage list, the Outsourcing Facilities Association filed a lawsuit against the FDA relating to the agency’s removal of tirzepatide, from the FDA’s drug shortage list.
23 October 2024
Foley Ignite
2024 Reflections and a Look Ahead to 2025: Examining Trends in M&A, Cross Border Financing, and AI
The mergers and acquisitions landscape in 2024 showed signs of recovery following the slump experienced in 2023.